New York, NY – October 31, 2018 – InvestorsHub NewsWire -- Generex Biotechnology Corp (OTCQB: GNBT) today announced a deal with HydRx Farms Ltd. which is more commonly known by its operating name, Scientus Pharma. Scientus is backed by none other than Canopy Growth (NYSE: CGC). Check out the bottom of page 5 of Canopy Growth’s Management Discussion & Analysis found on Canopy’s website to see their 9.9% HydRx ownership. Generex, by itself is no slouch. Generex, separate from Scientus and Canopy, has just filed an investigational new drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate Phase II Clinical Trials of a vaccine for patients with breast cancer. The Generex breast cancer vaccine was develop in conjunction with research conducted with Merck (NYSE: MRK). Together Scientus and Generex plan to deliver Scientus’s proprietary THC and CBD extractions via Generex’s RapdMist buccal mucosa delivery technology. In other words, a medicinal THC and CBD delivered a spray in your mouth.
Generex is currently a quiet giant of a pharmaceutical company that most people probably are not yet aware even exists. Do a little research and you will find Generex is loaded with proprietary, intellectual property protected pharmaceutical technology. Given its recent FDA trials announcement and today’s partnership with Scientus, Generex is likely ready to no longer be quiet about its gianthood.
Do a little more research and you will find the Generex has a pending 20:1 dividend coming soon. With just over one million shares currently issued and out, the dividend will take the issued and out just over 21 million with the holders of the roughly one million shares each getting 20 more shares for every share they own on the ex-dividend date. And no, the ex-dividend date has not yet been set, but looks to be coming soon.
At a $10 million market capitalization, given the market capitalization of GW Pharmaceuticals (GWPH) at $4 billion, not to mention the $100 million market capitalization of delinquent filer Cannabis Science (OTC: CBIS), GNBT seems extraordinarily undervalued. With GNBT’s IP portfolio, the current less than $10 PPS deserves to at least hold post the 20:1 dividend giving an investment now a potential 2000% ROI. Even if the PPS were to remain at its currentl level, that will still just be a $200 million market capitalization. The GNBT market cap likely has potential beyond $200 million giving a $10 per share investment now even a more dramatic upside opportunity.
Learn more about Generex at http://www.generex.com/
DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.